At the IGTP TODAY
The Immunology of Diabetes Group, led by Dr. Marta Vives-Pi, have published a paper in Scientific Reports on a successful combination therapy for a type 1 diabetes (T1D) model in Scientific Reports. In this study they continue their work on a drug that re-programmes pancreatic cells in mice with T1D), by combining it with an immunotherapy they have also developed.
Researchers from IGTP have published an article on the identification of a drug for beta cell regeneration in type 1 diabetes. The drug is already licenced for use in people with type 2 diabetes. Using artificial intelligence researchers selected the drug from 6,605 candidates and tested it in mouse models. The drug improved hyperglycaemia and results indicate that beta cell replacement took place. More research is needed to explore its use as a new therapy for beta cell regeneration, which should be combined with an immunomodulatory strategy to reduce autoimmunity.
To celebrate World Diabetes Day we will literally be talking about the illness at the IGTP; several members of the Immunology of Diabetes Group, which is led by Marta Vives-Pi and concentrates on research into diabetes type 1, will be taking part in talks and discussions in scientific and public forums during the next few days.
The Juvenile Diabetes Research Foundation (JDRF) is supporting a team of scientists that includes a group at the IGTP, led from the Andalusian research centre Cabimer, in their search for a cure for type 1 diabetes (T1D). Researchers in the Immunology of Diabetes Group at the IGTP are participating in the project as expert immunologists as they have wide experience of immunotherapies for T1D.
This Thursday the Llavaneres Golf Club hosted the 1st Pep Anglès Golf Tournament, a charity event for the Amics de Can Ruti (Friends of Can Ruti) and research at the IGTP. It is the first edition of the fundraising event organized by the player and his club and more than 10,000 euros have been raised for research into childhood diabetes at Can Ruti.
The Immunology of Diabetes Group at the IGTP has published its first results for their new research line on diabetes type 1 (T1D) in children, focussed on the mechanisms of the re-establishment of tolerance in children at the start of the disease and the definition of new biomarkers for its remission.
A new study by the Immunology of Diabetes Group, led by Marta Vives-Pi at the IGTP in conjunction with the University Medical Centre Hamburg-Eppendorf, builds on previous work led by the group in Hamburg. The new study looks into the effect of betamethasone on new-borns and its susceptibility to develop type 1 diabetes, when it is administered to mothers before birth. As well as corroborating the previous results and finding new changes in the developing immune system, the results also throw light onto the effect of the drug on the insulin-producing cells themselves.
The second edition of HEALTHIO, a trade fair for health and innovation at the Fira de Barcelona, was held on 16-18 October. It brought together members of the public, health professionals and innovative small companies in an open space designed to promote dialogue between all the players in the healthcare ecosystem and promote evolution of the sector.
From Vilanova i la Geltrú to Brussels by bicycle. This challenge was accepted by the father of a boy with diabetes type 1 (DT1) and member of the charity DiabetesCero, and on the way he managed get Euro MPs interested in the disease. His amazing journey has produced a meeting to discuss the DT1 on 21-22 June; Dr Marta Vives-Pi, Group Leader of the Immunology of Diabetes Group of the IGTP was there.
Researchers from the Immunology of Diabetes research group of the Germans Trias i Pujol Research Institute (IGTP) have confirmed, in human cells, that liposomes designed as immunotherapy for type 1 diabetes (T1D) are a valid strategy to arrest the autoimmune attack characteristic of this disease. They have done so in a preclinical study demonstrating the tolerogenic effect of these liposomes on cells of the immune system of patients with T1D. The results have been published in the journal Frontiers in Immunology.
